{"id":885455,"date":"2025-09-11T08:34:20","date_gmt":"2025-09-11T12:34:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/"},"modified":"2025-09-11T08:34:20","modified_gmt":"2025-09-11T12:34:20","slug":"absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/","title":{"rendered":"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD"},"content":{"rendered":"

\nPerformance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs
\n<\/h2>\n
\n

AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) — Absci<\/a>, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI)<\/a> and AMD<\/a> to accelerate generative AI-driven drug discovery. Absci\u2019s generative AI Drug Creation Platform leverages OCI\u2019s AI infrastructure and AMD\u2019s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.<\/p>\n

To advance Absci\u2019s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large\u2011scale molecular\u2011dynamics (MD) simulations and end\u2011to\u2011end antibody design. Absci is building on this success with OCI and partnering with AMD to further boost the performance and scalability of its AI Drug Creation Platform with AMD\u2019s next generation Instinct\u2122 MI355X GPUs.<\/p>\n

\u201cOur mission is to push the boundaries of how we design new therapeutics,\u201d said Sean McClain, Founder\u202fand\u202fCEO, Absci. \u201cWith OCI and AMD, we are pairing our cutting-edge AI models with best\u2011in\u2011class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI\u2011powered drug\u2011discovery workflows.\u201d<\/p>\n

\n Scaling AI-driven drug discovery with OCI and AMD<\/strong>\n <\/p>\n

OCI\u2019s bare metal instances, powered by 5th Generation AMD EPYC\u2122 processors and ultrafast RDMA cluster networking, give Absci the low-latency networking and throughput needed for large-scale model training and high-resolution molecular-dynamics simulations that refine antibody\u2013antigen interactions. With direct, bare-metal access to AMD GPUs in a single, flat-network supercluster, Absci has been able to eliminate hypervisor overhead, reduce inter-GPU latency to as little as 2.5 \u00b5s, and benefit from terabytes-per-second throughput for checkpointing and data streaming.<\/p>\n

\u201cAbsci\u2019s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for,\u201d said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences, Oracle. \u201cBy combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we\u2019re providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design.\u201d<\/p>\n

\u201cAbsci is demonstrating how AI can transform the pace of drug discovery, and we\u2019re proud to support that mission,\u201d said Ram Peddibhotla, corporate vice president, Data Center GPU Cloud Business, AMD. \u201cBy combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows.\u201d<\/p>\n

\n About Absci<\/strong>
\n
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation\u2122 platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci\u2019s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at\u00a0www.absci.com<\/u><\/a>\u00a0or follow us on LinkedIn (@absci<\/u><\/a>), X (@Abscibio<\/u><\/a>) and\u00a0YouTube<\/u><\/a>.<\/p>\n

\n About AMD<\/strong>
\n
For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ:AMD)\u00a0website<\/u><\/a>,\u00a0blog<\/u><\/a>,\u00a0LinkedIn<\/u><\/a>,\u00a0Facebook\u00a0<\/u><\/a>and\u00a0X<\/u><\/a>\u00a0pages.<\/p>\n

\n About Oracle<\/strong>
\n
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at\u00a0www.oracle.com<\/u><\/a>.<\/p>\n

\n Trademarks<\/strong>
\n
AMD, EPYC, AMD Instinct, ROCm and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.<\/p>\n

Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company\u2014ushering in the new era of cloud computing.\u202f\u00a0<\/p>\n

\n Contact Info<\/strong> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Absci
press@absci.com<\/u><\/a><\/p>\n

\n David Szabados<\/strong>
\n
AMD Communications
david.szabados@amd.com<\/u><\/a><\/p>\n

\n Julia Allyn<\/strong>
\n
Oracle
julia.allyn@oracle.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) — Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci\u2019s generative AI Drug Creation Platform leverages OCI\u2019s AI infrastructure and AMD\u2019s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles. To advance Absci\u2019s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate … <\/p>\n

Continue reading “Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-885455","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbsci Accelerates AI-Driven Drug Discovery with Oracle and AMD - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) — Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci\u2019s generative AI Drug Creation Platform leverages OCI\u2019s AI infrastructure and AMD\u2019s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles. To advance Absci\u2019s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate … Continue reading "Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-11T12:34:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD\",\"datePublished\":\"2025-09-11T12:34:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/\"},\"wordCount\":777,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/\",\"name\":\"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=\",\"datePublished\":\"2025-09-11T12:34:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/","og_locale":"en_US","og_type":"article","og_title":"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD - Market Newsdesk","og_description":"Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) — Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci\u2019s generative AI Drug Creation Platform leverages OCI\u2019s AI infrastructure and AMD\u2019s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles. To advance Absci\u2019s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate … Continue reading \"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-11T12:34:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD","datePublished":"2025-09-11T12:34:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/"},"wordCount":777,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/","name":"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=","datePublished":"2025-09-11T12:34:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNzE5MSM3MTQxNTk5IzIyMTAwODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-accelerates-ai-driven-drug-discovery-with-oracle-and-amd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/885455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=885455"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/885455\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=885455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=885455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=885455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}